ClinicalTrials.gg
TerminatedNCT05617755Updated Oct 29, 2026

AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer

A Phase 1 interventional study of AB-1015 in Carcinoma, Ovarian Epithelial, Ovarian Neoplasms and Fallopian Tube Neoplasms, sponsored by Arsenal Biosciences, Inc.. Terminated at 8 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Arsenal Biosciences, Inc. · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
Active patients have been rolled over to a separate LTFU study.

From the registry’s dates

  • Primary completion was Sep 2024, 2 years 1 month ago, and no results have been posted to the registry.
Updated Oct 29, 2026Now TerminatedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
19
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 500 studies in Carcinoma, Ovarian Epithelial with a site in United States — 28 open to participants now, 50 under way, 8 of them phase 3. Carcinoma, Ovarian Epithelial · United States.

Enrollment
281st of 381
19 · median 35
Started
2022
with 17 others
Phase 1
153 of 500
9 open now
Registered
473rd of 500
by date

Among the 500 studies in Carcinoma, Ovarian Epithelial with a site in United States, this one is the 281st largest by enrollment of the 381 interventional ones that give a count, is one of 18 that started in 2022, is one of 153 in phase 1, and was the 473rd registered.

Carcinoma, Ovarian Epithelial

798 studies on the registry are indexed under Carcinoma, Ovarian Epithelial; 101 are open to participants now.

Browse Carcinoma, Ovarian Epithelial studies →

Open to participants now

28 of the 500 studies in Carcinoma, Ovarian Epithelial with a site in United States are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 75 Carcinoma, Ovarian Epithelial studies recruiting now, 49 (65%) set no upper age limit and 12 (16%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 500 studies in Carcinoma, Ovarian Epithelial with a site in United States, or all of them as a file.
02

Study summary

This is a multi-center, open-label phase 1 dose escalation trial that uses a modified 3+3 design to identify a recommended phase 2 dose (RP2D) of AB-1015 cell product. Backfill cohorts will enroll additional subjects at doses deemed to be safe for a total enrollment of up to 12 subjects per each backfill cohort on the protocol.

Read the detailed description

This study is intended for the patients who have been diagnosed with Epithelial Ovarian Cancer that either came back or did not improve after platinum treatments (platinum resistant). The purpose of this study is to test the safety of using a new treatment called Integrated Circuit T (ICT) cells (AB-1015 cells) in patients with ovarian cancer. This treatment has not been approved by the Food and Drug Administration.

The goal of this study is to calculate the maximum tolerated dose of the AB-1015 cells. T cells are part of the immune system that protect the body from infection and may help fight cancer. The T cells given in this study will come from the patient and will have a genetic circuit/logic gate put in them that makes them able to recognize alkaline phosphatase, germ line/placental (ALPG/P) and mesothelin (MSLN), 2 proteins on the surface of tumor cells. These logic-gated T cells may help the body's immune system identify and kill cancer cells while sparing normal healthy tissues from toxicity.

The AB-1015 cells are given intravenously, after completing 3 rounds of conditioning chemotherapy administered over 3 consecutive days. Conditioning chemotherapy prepares the body to receive the AB-1015 cells. If they continue to meet the eligibility criteria, AB-1015 cells will be given to them 2 days after the last conditioning chemotherapy round. A single infusion of the AB-1015 cells will be given to the subject intravenously.

After completion of study treatment, patients are followed with serial measurements of safety, tolerability and response.

This is a research study to obtain new information that may help people in the future.

03

Conditions studied

  • Carcinoma, Ovarian Epithelial
  • Ovarian Neoplasms
  • Fallopian Tube Neoplasms
  • Peritoneal Neoplasms
  • Neoplasms, Glandular and Epithelial
  • Ovarian Diseases
  • Genital Neoplasm, Female
  • Abdominal Neoplasm
  • Recurrence

Keywords

  • ovarian cancer
  • fallopian tube cancer
  • primary peritoneal cancer
  • platinum resistant
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Recurrent, advanced, platinum resistant ovarian, fallopian tube, and primary peritoneal cancer and must have a histological diagnosis of a high-grade serous histology.
  • a) Platinum resistant disease is defined as progression of disease within six months of platinum regimen.
  • Doubling of cancer antigen 125 (CA-125) level on 2 successive measurements may be considered as meeting the definition of disease progression
  • b) Have received at least 2 including a platinum-based regimen if eligible and a poly-ADP ribose polymerase (PARP) inhibitor if BRCA1/2 mutated. No more than 3 lines of prior therapy for the treatment of platinum resistant disease is permitted.
  • Adequate organ function as per protocol definitions.
  • (ECOG) performance status score 0 or 1.
  • Evaluable disease (dose escalation cohorts) or (backfill cohorts) at time of enrollment as per protocol definitions.
  • Negative pregnancy test for women of . Women of non-childbearing potential are those who have been surgically sterilized, have medically confirmed ovarian failure, or have not had menses within the past 12 months.

Exclusion criteria

Exclusion Criteria:

  • Cytotoxic chemotherapy within 14 days of time of cell collection.
  • Cytotoxic chemotherapy within 14 days of starting of conditioning chemotherapy.
  • functional class II-IV cardiovascular disability
  • pericardial effusion
  • Pleural or peritoneal effusion that requires drainage for symptom management within 28 days of screening.
  • Active disease requiring therapy or uncontrolled with treatment.
  • Untreated .
  • Subjects unwilling to participate in an extended safety monitoring period.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    AB-1015

    Patients receive fludarabine and cyclophosphamide intravenously on days -5 to -3. Patients receive a single dose of AB-1015 intravenously on day 0.

    Biological: AB-1015

Interventions

  • BiologicalAB-1015

    autologous T cell therapy

    Also known as: Integrated Circuit T (ICT) cells

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events and dose limiting toxicities (DLTs)

    Toxicity grading will be evaluated according to the Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events version 5.0 and monitoring of adverse events. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) events will be graded according to the criteria outlined in the protocol.

    Time frame: Up to 2 years post treatment

  2. Maximal tolerated dose of AB-1015

    Will be determined by a 3x3 dose escalation study

    Time frame: Up to 21 days

Secondary outcomes

  1. Number of AB-1015 cells

    Number of AB-1015 cells present in patients treatment with AB-1015

    Time frame: Up to 1 year post treatment

  2. Evidence of anti-tumor activity

    Assessed according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1

    Time frame: Up to 2 years post treatment

  3. Co-expression of ALPG and MSLN targets on tumor cells

    Assessment by immunohistochemistry (or similar method)

    Time frame: Up to 2 years post treatment

07

Study locations

8 sites
  • UCSF Helen Diller Family Comprehensive Cancer Center
    San Francisco, California 94158, United States
  • U of Colorado Cancer Center - Anschutz Medical Campus
    Aurora, Colorado 80045, United States
  • U of Iowa Health Care
    Iowa City, Iowa 52242, United States
  • Barbara Ann Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Roswell Park Comprehensive Cancer Center
    Buffalo, New York 14203, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • U of Washington - Fred Hutchinson Cancer Center
    Seattle, Washington 98195, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Nov 2022 to primary completion in Sep 2024, 22 months.

Completion moved once since we started tracking on Sep 25, 2026: Feb 2027 → Oct 2026, on Oct 29, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2022
First posted
Nov 15, 2022
StartActual
Nov 29, 2022
Primary completionActual
Sep 30, 2024
CompletionActual
Oct 26, 2026was Feb 2027
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated Active patients have been rolled over to a separate LTFU study.
changed Oct 29, 2026
Study completion
Feb 2027→Oct 26, 2026 (actual)
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Active, not recruiting→Terminated
    Why stopped Active patients have been rolled over to a separate LTFU study.
    Study completion Feb 2027→Oct 26, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05617755
Lead sponsor
Arsenal Biosciences, Inc.
Responsible party
Sponsor
First posted
Nov 15, 2022
Start date
Nov 29, 2022
Primary completion
Sep 30, 2024
Completion
Oct 26, 2026
Last update
Oct 29, 2026

Study contacts

Arsenal Biosciences
study director · Arsenal Biosciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion